Publications by authors named "G Ishikawa"
Background/aim: Immuno-oncology (IO) improves the prognosis of advanced renal cell carcinoma (RCC). Since research has so far been limited to clinical trials, we herein focused on the effects of IO-tyrosine kinase inhibitor (TKI) combination therapy in real-world clinical settings.
Patients And Methods: We conducted a retrospective study on 125 patients with advanced RCC who received IO-TKI combination therapy or TKI monotherapy.
Wheat yellow mosaic disease is a soilborne disease caused by (WYMV). Symptoms include yellow mosaic coloring of leaves, stunting, and growth inhibition. Here we conducted a detailed analysis of resistance to this virus in winter wheat 'Hokkai 240' by carrying out inoculation tests of WYMV and conducting field tests.
View Article and Find Full Text PDFArticle Synopsis
- Enfortumab Vedotin (EV) is an effective treatment for advanced urothelial carcinoma (UC) patients who have already undergone other therapies, but there’s limited understanding of the factors that impact patient outcomes.
- A retrospective study was conducted to identify clinical factors affecting progression-free survival (PFS) and overall survival (OS) in these patients, leading to the development of a new risk classification model based on identified prognostic factors.
- The study found that high levels of C-reactive protein and hypercalcemia were significant predictors of patient outcomes, allowing for the classification of patients into three distinct risk groups, which showed notable differences in survival rates.
Article Synopsis
- Combined treatment of lenvatinib and pembrolizumab is a standard first-line therapy for advanced renal cell carcinoma (aRCC) patients, and this study aimed to evaluate its effectiveness and safety in Japanese patients who hadn't received prior treatment.
- A total of 50 treatment-naïve aRCC patients were analyzed, revealing a 66% overall response rate, with 14% achieving complete responses and 52% having partial responses; the patients were classified into risk groups showing varied response rates.
- The study concluded that the combined regimen's real-world efficacy and safety profiles are comparable to those seen in previous randomized clinical trials, with a notable incidence of adverse events in the patient population.
Tissue fibrosis contributes to pathology in vital organs including the lung. Curative therapies are scant. Myofibroblasts, pivotal effector cells in tissue fibrosis, accumulate via incompletely understood interactions with their microenvironment.
View Article and Find Full Text PDF